Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
NCT ID: NCT00418886
Last Updated: 2024-12-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
698 participants
INTERVENTIONAL
2007-01-31
2023-02-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Placebo Vandetanib + Pemetrexed
Pemetrexed
intravenous infusion
2
Vandetanib + Pemetrexed
Vandetanib
oral once daily tablet
Pemetrexed
intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vandetanib
oral once daily tablet
Pemetrexed
intravenous infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female or male aged 18 years or above
* Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (stage IIIB or IV) on entry into study
* Failure of 1st line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) or subsequent relapse of disease following 1st line therapy
* WHO Performance status 0 - 2
* One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral CT scan or 20 mm with conventional techniques according to RECIST criteria. Previously irradiated lesions will not be considered measurable.
* Life expectancy of 12 weeks or longer
* Negative pregnancy test for women of childbearing potential only
Exclusion Criteria
* Patients have received 2nd-line or subsequent anti-cancer therapy
* Prior treatment with pemetrexed
* Prior treatment with VEGFR TKIs (previous treatment with bevacizumab \[Avastin\] is permitted)
* Known or suspected brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable without steroid treatment for 10 days
* The last radiation therapy within 4 weeks before the start of study therapy, not including local palliative radiation
* The last dose of prior chemotherapy or other anti-cancer therapy is discontinued less than 3 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin, and suramin)
* Major surgery within 4 weeks before entry, or incompletely healed surgical incision
* Neutrophils \<1.5 x 109/L or platelets \<100 x 109/L
* Serum bilirubin \>1.5 x the upper limit of reference range (ULRR)
* Creatinine clearance \<50 ml/min calculated by either Cockcroft -Gault, 24 hours urine collection, EDTA scan or other validated methods
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 x ULRR in the absence of liver metastases, or \> 5 x ULRR in the presence of liver metastases
* Alkaline phosphatase (ALP) \>2.5 x ULRR in the absence of liver metastases, or \>5 x ULRR in the presence of liver metastases
* Current active gastrointestinal disease that may affect the ability of the patient to absorb ZD6474 or tolerate diarrhoea
* Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol
* Any unresolved toxicity greater than CTCAE Grade 2 from previous anti-cancer therapy
* Significant cardiovascular event (e.g., myocardial infarction, superior vena cava \[SVC\] syndrome), New York Heart Association \[NYHA\] classification of heart disease ≥2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia
* History of arrhythmia (multifocal premature ventricular contractions \[PVCs\], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded
* Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age
* QT prolongation with other medications that required discontinuation of that medication
* Presence of left bundle branch block (LBBB)
* QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG (Note: If a patient has QTc interval ≥480 msec on screening ECG, the screen ECG may be repeated twice \[at least 24 hours apart\]. The average QTc from the three screening ECGs must be \<480 msec in order for the patient to be eligible for the study) Patients who are receiving a drug that has a risk of QTc prolongation are eligible if QTc is \<460 msec.
* Potassium \<4.0 mmol/L despite supplementation; serum calcium (or ionized or adjusted for albumin), or magnesium out of normal range despite supplementation
* Women who are pregnant or breast-feeding
* Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function. Drugs that have a risk of QTc prolongation, that in the investigator's opinion cannot be discontinued, are allowed, but only of the QTc is \<460 msec
* Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 millimetre of mercury \[mmHg\] or diastolic blood pressure greater than 100 mmHg)
* Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or squamous cell carcinoma of the skin
* Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment
* Concomitant use of yellow fever vaccine or any live attenuated vaccines
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Casa Grande, Arizona, United States
Research Site
Chandler, Arizona, United States
Research Site
Farmington, Connecticut, United States
Research Site
Stamford, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Orlando, Florida, United States
Research Site
Gainesville, Georgia, United States
Research Site
Skokie, Illinois, United States
Research Site
Sioux City, Iowa, United States
Research Site
Mount Sterling, Kentucky, United States
Research Site
Portland, Maine, United States
Research Site
Baltimore, Maryland, United States
Research Site
Rockville, Maryland, United States
Research Site
Boston, Massachusetts, United States
Research Site
St Louis, Missouri, United States
Research Site
Mineola, New York, United States
Research Site
Rochester, New York, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Middletown, Ohio, United States
Research Site
Hilton Head Island, South Carolina, United States
Research Site
Austin, Texas, United States
Research Site
Salt Lake City, Utah, United States
Research Site
Avellaneda, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
Córdoba, , Argentina
Research Site
La Plata, , Argentina
Research Site
Ramos Mejía, , Argentina
Research Site
Salta, , Argentina
Research Site
Santa Fe, , Argentina
Research Site
Chermside, , Australia
Research Site
Fitzroy, , Australia
Research Site
Footscray, , Australia
Research Site
Heidelberg, , Australia
Research Site
Randwick, , Australia
Research Site
St Leonards, , Australia
Research Site
Wodonga, , Australia
Research Site
Brussels (Woluwé-St-Lambert), , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Bogotá, , Colombia
Research Site
Medellín, , Colombia
Research Site
Pereira, , Colombia
Research Site
Valledupar, , Colombia
Research Site
Avignon, , France
Research Site
Lyon, , France
Research Site
Paris, , France
Research Site
Pontoise, , France
Research Site
Strasbourg, , France
Research Site
Cologne, , Germany
Research Site
Hanover, , Germany
Research Site
Karlsruhe, , Germany
Research Site
Kassel, , Germany
Research Site
Leipzig, , Germany
Research Site
N. Faliro, , Greece
Research Site
Pátrai, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Hong Kong, , Hong Kong
Research Site
Ahmedabad, , India
Research Site
Vellore, , India
Research Site
Beer-Sheeva, , Israel
Research Site
Haifa, , Israel
Research Site
Jerusalem, , Israel
Research Site
Kfar Saba, , Israel
Research Site
Petah Tikva, , Israel
Research Site
Safed, , Israel
Research Site
Tel Litwinsky, , Israel
Research Site
Ẕerifin, , Israel
Research Site
Genova, , Italy
Research Site
Milan, , Italy
Research Site
Orbassano, , Italy
Research Site
Roma, , Italy
Research Site
S.Andrea Delle Fratte, , Italy
Research Site
Aguascalientes, , Mexico
Research Site
México, , Mexico
Research Site
Puebla City, , Mexico
Research Site
Cebu City, , Philippines
Research Site
Manila, , Philippines
Research Site
Pasay, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Lisbon, , Portugal
Research Site
Santa Maria da Feira, , Portugal
Research Site
Setúbal, , Portugal
Research Site
Cape Town, , South Africa
Research Site
Durban, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Port Elizabeth, , South Africa
Research Site
Pretoria, , South Africa
Research Site
A Coruña, , Spain
Research Site
Lugo, , Spain
Research Site
Majadahonda, , Spain
Research Site
Mataró(Barcelona), , Spain
Research Site
Málaga, , Spain
Research Site
Ourense, , Spain
Research Site
Santiago de Compostela(A Coru, , Spain
Research Site
Vigo(Pontevedra), , Spain
Research Site
Lund, , Sweden
Research Site
Sundsvall, , Sweden
Research Site
Umeå, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Västerås, , Sweden
Research Site
Taipei, , Taiwan
Research Site
Birmingham, , United Kingdom
Research Site
Edinburgh, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Wolverhampton, , United Kingdom
Research Site
Caracas, , Venezuela
Research Site
Valencia, , Venezuela
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011 Mar 10;29(8):1067-74. doi: 10.1200/JCO.2010.29.5717. Epub 2011 Jan 31.
Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
CSR-D4200C00036.pdf
Vandetanib\_study\_36\_ZEAL\_CSP\_redacted\_SECURE
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUDRACT No. 2006-003695-35
Identifier Type: -
Identifier Source: secondary_id
LPS15296
Identifier Type: OTHER
Identifier Source: secondary_id
D4200C00036
Identifier Type: -
Identifier Source: org_study_id